Read the following passage carefully:
The accelerating deployment of population-scale genomic biobanks in developing nations is frequently championed as a transformative leap toward precision medicine and equitable healthcare delivery. Proponents argue that harvesting indigenous genomic data addresses the historical underrepresentation of non-European populations in global biomedical research, thereby enabling tailored therapeutic interventions. However, this optimism obscures structural vulnerabilities inherent in transnational genomic governance. Most biobanking initiatives rely heavily on foreign venture capital and external technical infrastructure, creating asymmetrical dependencies wherein host nations supply biological capital while multinational pharmaceutical corporations retain the resulting intellectual property and patent rights. Furthermore, existing legislative frameworks in these nations rarely distinguish between sovereign biological resources and commercialized genetic commodities, leaving populations vulnerable to biopiracy and digital extractive regimes. Rather than fostering genuine domestic scientific capacity, unregulated biobanking risks institutionalizing a modern form of biocolonialism under the rubric of global health equity. To avert this outcome, multilateral policy architectures must move beyond mere consent protocols to establish binding frameworks for genomic data sovereignty, benefit-sharing mechanisms, and national technology transfer. Without such institutional safeguards, population genomic initiatives will inevitably exacerbate, rather than alleviate, global healthcare disparities.
Which of the following options best reflects the central theme of the passage?
- Unregulated population biobanking in developing nations risks perpetuating asymmetrical biocolonial exploitation unless governed by binding frameworks for genomic sovereignty and benefit-sharing.Answer
- BPopulation-scale biobanking in developing nations should be entirely banned due to the inherent impossibility of obtaining valid informed consent from vulnerable populations.
- CThe principal barrier to precision medicine among non-European populations is the historical deficiency of foreign venture capital invested in domestic clinical infrastructure.
- DTransnational genomic initiatives represent intentional predatory schemes orchestrated by multinational corporations to systematically destroy local health systems.